These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21849281)

  • 1. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies.
    Verstrepen BE; Depla E; Rollier CS; Mares G; Drexhage JA; Priem S; Verschoor EJ; Koopman G; Granier C; Dreux M; Cosset FL; Maertens G; Heeney JL
    J Infect Dis; 2011 Sep; 204(6):837-44. PubMed ID: 21849281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies.
    Tarr AW; Backx M; Hamed MR; Urbanowicz RA; McClure CP; Brown RJP; Ball JK
    Antiviral Res; 2018 Dec; 160():25-37. PubMed ID: 30217650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.
    Chen F; Nagy K; Chavez D; Willis S; McBride R; Giang E; Honda A; Bukh J; Ordoukhanian P; Zhu J; Frey S; Lanford R; Law M
    Gastroenterology; 2020 Mar; 158(4):1058-1071.e6. PubMed ID: 31809725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
    Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
    Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
    J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus.
    Meunier JC; Gottwein JM; Houghton M; Russell RS; Emerson SU; Bukh J; Purcell RH
    J Infect Dis; 2011 Oct; 204(8):1186-90. PubMed ID: 21917891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
    Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
    PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice.
    Masavuli MG; Wijesundara DK; Underwood A; Christiansen D; Earnest-Silveira L; Bull R; Torresi J; Gowans EJ; Grubor-Bauk B
    Front Immunol; 2019; 10():1145. PubMed ID: 31178869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
    Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
    Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
    Ruwona TB; Giang E; Nieusma T; Law M
    J Virol; 2014 Sep; 88(18):10459-71. PubMed ID: 24965471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice.
    Zhu F; Wang Y; Xu Z; Qu H; Zhang H; Niu L; Xue H; Jing D; He H
    Mol Med Rep; 2019 Feb; 19(2):1016-1023. PubMed ID: 30569131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees.
    Bassett SE; Thomas DL; Brasky KM; Lanford RE
    J Virol; 1999 Feb; 73(2):1118-26. PubMed ID: 9882313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
    Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
    Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster.
    Reyes-del Valle J; de la Fuente C; Turner MA; Springfeld C; Apte-Sengupta S; Frenzke ME; Forest A; Whidby J; Marcotrigiano J; Rice CM; Cattaneo R
    J Virol; 2012 Nov; 86(21):11558-66. PubMed ID: 22896607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles.
    Kachko A; Kochneva G; Sivolobova G; Grazhdantseva A; Lupan T; Zubkova I; Wells F; Merchlinsky M; Williams O; Watanabe H; Ivanova A; Shvalov A; Loktev V; Netesov S; Major ME
    Vaccine; 2011 Dec; 30(1):69-77. PubMed ID: 22041300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast.
    Cai W; Su L; Liao Q; Ye L; Wu Y; Wu Z; She Y
    Antiviral Res; 2010 Oct; 88(1):80-5. PubMed ID: 20691736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer.
    Guest JD; Wang R; Elkholy KH; Chagas A; Chao KL; Cleveland TE; Kim YC; Keck ZY; Marin A; Yunus AS; Mariuzza RA; Andrianov AK; Toth EA; Foung SKH; Pierce BG; Fuerst TR
    Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.